[ad_1]
The number of thromboembolic events after administration of the AstraZeneca vaccine is lower than for other Covid-19 vaccines, however, the mortality rate observed so far was higher for the Anglo-Swedish vaccine, informed the safety committee of the European Medicines Agency (PRAC), in a report published on Wednesday.
The report also indicates that, as of March 11, 269 cases of embolic or thromboembolic events had been reported on the EudraVigilance platform of the European Medicines Agency (EMA), 202 of them serious. Of the 269 cases, 224 were registered in the United Kingdom and 30 in the European Economic Area.
Most of the recorded cases (60%) occurred in women and the majority the average age was 70 years. Of the cases in the European Economic Area (EEA), 14 people had risk factors for the development of thromboembolic events, such as hypertension, thyroid problems, obesity or chronic hepatitis.
Two 269 cases, 45 cases resulted in the death of patients. In the EEA there were seven fatalities, ranging in age from 24 to 60 years.
The EMA indicates that, based on the cases analyzed, no specific risk factors were found associated with age, sex, or clinical history of coagulation. It was not possible to link these rare events to vaccine administration, “but it is possible and research will continue.”
On Wednesday, the EMA director said the regulator is investigating 62 cases of blood clots around the world, 44 of them in the EEA, where 9.2 million people have already received at least one dose of the vaccine, Reuters reported.
The safety committee report specifies that a time pattern was detected (the events occurred after vaccination) and that the most common problem reported was low platelets. The report also indicates that the majority of the patients were young adult women, but this can also be accounted for by the fact that this is ultimately the group of people with the most AstraZeneca vaccines administered.
[ad_2]
